相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Beacon Biosignals completed a $97 million Series B financing round, bringing total cumulative funding to over $132 million to advance brain health diagnostics. - The company combines FDA-cleared wearable EEG technology with advanced AI to capture real-world neural data for neurology, psychiatry, and sleep medicine applications. - New investors including JSL Health, Palo Santo VC, and Samsung Next joined the round to support scalable at-home EEG solutions for clinical trials and precision medicine. - The platform is positioned to play a critical role in measuring brain-based outcomes for emerging psychiatric treatments, including novel psychedelic therapeutics.
- Beacon Biosignals raised an oversubscribed $86 million Series B funding round to build the world's largest neurodiagnostic dataset and advance AI-driven biomarkers for brain health. - The company's FDA-cleared Waveband device directly measures brain electrical activity through EEG during sleep and wake, bringing gold-standard neurophysiology from lab to home settings. - Beacon's technology now supports research programs with more than half of the world's top ten biopharmaceutical companies, leveraging AI-derived biomarkers to accelerate CNS drug development. - The funding will scale operations to accelerate neurobiomarker discovery across neurological and psychiatric conditions including depression, Parkinson's disease, Alzheimer's disease, and sleep apnea.
- Iterum Therapeutics has appointed Christine Coyne as Chief Commercial Officer to lead the upcoming U.S. launch of ORLYNVAH, an FDA-approved oral antibiotic for uncomplicated urinary tract infections. - Coyne brings over 30 years of pharmaceutical commercial experience, including previous roles as Chief Commercial Officer at Innoviva and SCYNEXIS, with specific expertise in anti-infective portfolios. - ORLYNVAH represents a novel oral penem antibiotic targeting multi-drug resistant pathogens, including those with extended spectrum beta-lactamase resistance, addressing significant unmet medical needs. - The appointment comes at a pivotal time as Iterum prepares for commercial launch with partner EVERSANA, positioning the company for sustained growth in the anti-infective market.
- Syndeio Biosciences launched with $90 million in funding to develop the first synapse-targeted therapeutics for neurological and psychiatric disorders affecting over one billion people globally. - The company's lead candidate zelquistinel is advancing through Phase II trials for major depressive disorder and will enter the first-ever Alzheimer's trial using synaptic function biomarkers as endpoints. - Founded by former Karuna Therapeutics and Naurex executives alongside Nobel Laureate Thomas Südhof, Syndeio aims to restore neural connections through proprietary event-driven pharmacology platform. - The biotech targets synaptopathies including major depressive disorder, Alzheimer's disease, and schizophrenia by strengthening weakened synaptic connections that underlie these conditions.
- The Salford Lung Study shows patients using Relvar Ellipta had double the odds of achieving improved asthma control compared to standard care treatments. - The groundbreaking 52-week open-label trial involved 4,233 patients and was designed to reflect real-world clinical practice with minimal exclusion criteria. - Despite promising control outcomes, Relvar Ellipta carries boxed warnings for asthma-related death risk in children and adolescents, limiting its use in these populations.
